Literature DB >> 16619578

Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas--experience and meta-analysis.

Anouk N A Van Der Horst-Schrivers1, Pieter L Jager, H Marike Boezen, Jan P Schouten, Ido P Kema, Thera P Links.   

Abstract

BACKGROUND: Recommendations on the use of I-123 metaiodobenzylguanidine (MIBG) scintigraphy in localising phaeochromocytomas vary. The accuracy of I-123 MIBG scintigraphy was determined by evaluating our own I-123 MIBG scans and performing a meta-analysis.
MATERIALS AND METHODS: Between January 1992 and May 2002, the I-123 MIBG scans of consecutive patients suspected of a phaeochromocytoma were re-evaluated. For the meta-analysis, studies with more than 5 I-123 MIBG scans were selected.
RESULTS: Thirty patients were evaluated. The sensitivity in our own population was 92% and the specificity was 100%. Twelve articles were selected for our meta-analysis. The overall sensitivity and specificity were 96% and 100%, respectively. The sensitivity and specificity for tumours in the adrenal gland was 98% for both. For tumours located outside the adrenal gland, the sensitivity was 98% and the sensitivity for malignancies was 79%.
CONCLUSION: 1-123 MIBG scintigraphy has an excellent sensitivity and specificity in localising phaeochromocytomas, except for malignant tumours. 1-123 MIBG scintigraphy is superior in localising tumours outside the adrenal gland.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16619578

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  18 in total

1.  Routine preoperative (123)I-MIBG scintigraphy for patients with phaeochromocytoma is not necessary.

Authors:  Radu Mihai; Fergus Gleeson; Derek Roskell; Andrew Parker; Greg Sadler
Journal:  Langenbecks Arch Surg       Date:  2008-07-29       Impact factor: 3.445

2.  Use of 6-[18F]-fluorodopamine positron emission tomography (PET) as first-line investigation for the diagnosis and localization of non-metastatic and metastatic phaeochromocytoma (PHEO).

Authors:  Henri J L M Timmers; Graeme Eisenhofer; Jorge A Carrasquillo; Clara C Chen; Millie Whatley; Alexander Ling; Karen T Adams; Karel Pacak
Journal:  Clin Endocrinol (Oxf)       Date:  2008-12-05       Impact factor: 3.478

Review 3.  Current and future anatomical and functional imaging approaches to pheochromocytoma and paraganglioma.

Authors:  H J L M Timmers; D Taieb; K Pacak
Journal:  Horm Metab Res       Date:  2012-03-07       Impact factor: 2.936

4.  Pheochromocytoma and paraganglioma.

Authors:  Vitaly Kantorovich; Karel Pacak
Journal:  Prog Brain Res       Date:  2010       Impact factor: 2.453

Review 5.  Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.

Authors:  Ioannis Ilias; Chaitanya Divgi; Karel Pacak
Journal:  Semin Nucl Med       Date:  2011-09       Impact factor: 4.446

Review 6.  Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.

Authors:  Oliver Gimm; Catherine DeMicco; Aurel Perren; Francesco Giammarile; Martin K Walz; Laurent Brunaud
Journal:  Langenbecks Arch Surg       Date:  2011-11-29       Impact factor: 3.445

7.  Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial.

Authors:  Gregory A Wiseman; Karel Pacak; Mary S O'Dorisio; Donald R Neumann; Alan D Waxman; David A Mankoff; Sherif I Heiba; Aldo N Serafini; Sabah S Tumeh; Natalie Khutoryansky; Arnold F Jacobson
Journal:  J Nucl Med       Date:  2009-08-18       Impact factor: 10.057

Review 8.  A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors.

Authors:  Ioannis Ilias; Karel Pacak
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

Review 9.  Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome.

Authors:  Karel Pacak; Graeme Eisenhofer; Ioannis Ilias
Journal:  Hormones (Athens)       Date:  2009 Apr-Jun       Impact factor: 2.885

10.  Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.

Authors:  Henri J L M Timmers; Clara C Chen; Jorge A Carrasquillo; Millie Whatley; Alexander Ling; Bastiaan Havekes; Graeme Eisenhofer; Lucia Martiniova; Karen T Adams; Karel Pacak
Journal:  J Clin Endocrinol Metab       Date:  2009-10-28       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.